Research programme: atopic dermatitis therapeutic - NeoPharm
Latest Information Update: 14 Jul 2016
At a glance
- Originator NeoPharm Co
- Class Skin disorder therapies
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Atopic dermatitis
Most Recent Events
- 14 Jul 2016 No recent reports on development identified for Atopic dermatitis in South Korea (unspecified route)